Orforglipron cardiovascular safety holds against insulin glargine in ACHIEVE 4

Eli Lilly's daily pill orforglipron did not add heart risk against insulin glargine in ACHIEVE-4, a Phase 3 outcomes trial in people with type 2 diabetes and heart or kidney disease. The study is the first full test of orforglipron cardiovascular safety, a question that had not been studied for any non-peptide GLP-1 receptor agonist. The Lancet paper went online on 30 September and is now drawing wider clinical coverage. The molecule stays at the approved stage on our board, with a modest signal up for its diabetes case.

What the ACHIEVE 4 trial tested

The ACHIEVE-4 trial was event driven, open label and run against an active comparator. It enrolled 2,749 adults at 317 sites in 16 countries and territories, and 62.5% were men, according to the Lancet paper as summarised by Physicians Weekly. Everyone had type 2 diabetes with established cardiovascular or chronic kidney disease, an HbA1c between 7.0% and 10.5%, a BMI of at least 25, and up to three background drugs drawn from metformin, a sulfonylurea or an SGLT2 inhibitor. Investigators assigned 1,371 people to the orforglipron pill, taken once a day and stepped up to the highest amount each person tolerated. The other 1,378 took once daily insulin glargine injections, adjusted over time to reach blood sugar targets.

This was an older and higher risk group than a typical weight loss study. Mean age was 63, mean HbA1c was 8.2% and mean BMI was 33, and 85.9% of participants had established cardiovascular disease while 37.5% had chronic kidney disease. The primary goal was narrow: show that orforglipron is not worse than insulin glargine on time to a first MACE-4 event. That composite counts cardiovascular death, nonfatal heart attack, nonfatal stroke and hospital admission for unstable angina, so it captures a slightly wider set of events than death, heart attack and stroke alone. Eli Lilly sponsored the study and makes orforglipron, a point the meeting release states plainly, and readers should keep that in view when weighing the paper.

Heart events and deaths in the results

Over a median follow up of two years, MACE-4 occurred in 57 of 1,358 people on orforglipron (4.2%) and in 67 of 1,343 on insulin glargine (5.0%). The hazard ratio was 0.84. That 16% lower figure was not statistically significant, but it met the statistical test for non-inferiority, which is the primary question the trial was designed to answer. Deaths were also fewer on the pill, at 19 (1.4%) against 43 (3.2%), and all but one death, in the glargine group, were judged unrelated to treatment. So the orforglipron cardiovascular safety result clears a regulatory style hurdle without proving a benefit. The mortality gap is striking, yet it should be read as an observation rather than as a proven effect of the drug.

That 16% lower figure was not statistically significant, but it met the statistical test for non-inferiority, which is the primary question the trial was designed to answer.

The trial fills a specific gap. Some peptide GLP-1 receptor agonists have shown cardiovascular benefit in their own outcome trials, while heart safety for non-peptide agonists had not been studied, according to a news release from EASD. ACHIEVE-4 now answers the safety question for one small molecule. It does not answer the benefit question, because insulin glargine is an active drug rather than a placebo and the study was built around non-inferiority. That leaves the peptide incumbents with a claim the pill cannot yet match. A doctor choosing between an injected peptide with outcome benefit data and a pill with safety data is weighing two different kinds of evidence, and this paper does not close that gap.

Blood sugar and weight gains come with more stomach side effects

Orforglipron beat insulin glargine on the key secondary measures. HbA1c fell 0.50 percentage points more and body weight fell 8.9 percentage points more on the pill, and both gaps held through 104 weeks, the authors report. At week 52, 65.7% of people on orforglipron reached an HbA1c below 7.0%, against 46.0% on glargine. For weight, 35.6% lost at least a tenth of their body weight on the pill versus 4.4% on insulin. The authors add that markers of kidney function and damage may improve, a signal they describe with care. Insulin glargine is not a weight loss drug, so the weight gap says little about how the pill compares with peptide GLP-1 rivals.

The cost shows up in the gut. Gastrointestinal side effects were reported by 62.1% of people on orforglipron and 14.2% on insulin glargine. The release says these events were the most common reason for stopping the pill and that more people discontinued orforglipron than glargine, though it gives no discontinuation rates. On the other side, clinically significant or severe hypoglycaemia was much less frequent with the pill, at 6.8% versus 19.2%. That trade between stomach upset and fewer low blood sugar episodes is the main safety choice the paper puts in front of prescribers. The open label design also meant participants and doctors knew which drug was given, which can colour how side effects get reported.

What changes for the oral GLP 1 race

On our board orforglipron already sits at the approved stage. The meeting release says it is cleared for obesity in the United States since April 2026 and in the United Kingdom since August 2026. In Europe, the drug won a positive CHMP opinion for Foundayo in October covering weight management and type 2 diabetes. ACHIEVE-4 does not move the stage. It adds a layer of orforglipron cardiovascular safety evidence that diabetes prescribers and payers are likely to ask about before using the drug in high risk patients. The material we reviewed does not say how Lilly will use the data in label talks, so any label change stays unconfirmed for now.

The race this result shifts is the one against peptide GLP-1 drugs, including the oral semaglutide pill from Novo Nordisk. A Lilly funded indirect comparison with oral semaglutide gave the pill a narrow efficacy edge, but modelled data cannot speak to heart safety. An outcome trial now exists for this oral GLP-1 pill, but against insulin rather than a peptide. Peptide rivals face the same test, and Boehringer Ingelheim's survodutide heart safety trial is on the AHA program with results still unseen. Klein, the corresponding author, said the study "reaffirmed the safety of orforglipron while demonstrating clinically meaningful improvements in blood sugar control and weight." Her view that the pill could widen access is a hope, not a measured outcome.

Conclusion

ACHIEVE-4 settles the first question about orforglipron cardiovascular safety: against insulin glargine in high risk type 2 diabetes, the pill did not add heart events over two years. It did not show heart protection, it caused far more stomach side effects, and the trial was open label and Lilly sponsored. The stage stays approved. The next tests are how regulators treat the data in diabetes labels and whether Lilly reports outcome data against a peptide GLP-1. This is research reporting, not medical advice.